Study details
Enrolling now
MMA Embolization for Refractory Chronic Migraine
Cerenovus, Part of DePuy Synthes Products, Inc.
NCT IDNCT06735833ClinicalTrials.gov data as of Apr 2026
Target enrollment
50
Study length
about 3.7 years
Ages
18–65
Locations
9 sites in AZ, CA, CT +4
About this study
Researchers are testing a new way to treat severe migraines that haven't responded to other treatments. The treatment involves blocking blood flow in the middle meningeal artery using a device. The trial will last about 1346 days and aims to enroll around 50 adults.
Based on ClinicalTrials.gov records.
What participants do
- 1.Use Middle Meningeal Artery embolization
Primary goalChange from baseline, in number of migraine days
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low5%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Change from baseline, in number of migraine days
Secondary: Change from baseline in migraine days frequency
Body systems
Neurology